[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"beta-blockers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:beta-blockers":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100555206",false,"NCT06509074","Beta-Blockers in Takotsubo Syndrome Study","Beta-Blockers in Takotsubo Syndrome Study: A Randomized Clinical Trial (β-Tako)","β-Tako","Inclusion Criteria:\n\n* Written informed consent.\n* Diagnosis of TTS with exclusion of significant coronary artery disease (CAD) by invasive coronary angiography\n\nExclusion Criteria:\n\n* Patients diagnosed of TTS \\> 48 hours before.\n* Persistent ccardiogenic shock or severe hemodynamic instability\n* Persistent severe (\\>30 mmHg) intraventricular gradient\n* Previous diagnosis of severe valvular or ventricular disease or prior myocardial infarction secondary to atherosclerotic CAD\n* Patients already receiving treatment with betablockers (\\*)\n* Absolute contraindication\u002Findication for beta-blockers (\\*\\*)\n* Poor echocardiographic window\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial.\n\n(\\*) Betablockers at a therapeutic dose at the time of symptom´s onset. (\\*\\*) Close ECG monitoring required in patients with hypotension, bradycardia or cQT interval prolongation","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The Beta-blockers in Takotsubo syndrome (TTS) (β-Tako) trial, is an academic, pragmatic, prospective, multicenter randomized clinical trial, aiming to assess the efficacy of beta-blockers (BB) in TTS patients. Two-hundred patients with TTS will be randomized (1:1) to BB (n=100) or no BB (n=100). BB with alpha or nitric oxide release activity will be used in the treatment arm. The primary endpoint will be the comparison of the wall motion score index by echocardiography at 7 days. A composite clinical endpoint (death, stroke, admission for recurrent TTS, ACS, heart failure or atrial fibrillation) at 1 year, will be assessed by an independent clinical events committee. Several sub-studies will be performed. The β-Tako trial will inform treatment decisions in this uniquely challenging clinical entity.",[26,27,28,29],"Takotsubo Cardiomyopathy","Beta-blockers","Echocardiography","Left Ventricular Function",[26,31,32,33,34,35,36,37,38,39],"beta-blockers","echocardiography","left ventricular function","acute myocardial infarction","acute coronary syndrome","coronary angiography","Normal coronary arteries","Heart failure","stress","NOT_YET_RECRUITING","2024-08-21",{"date":43,"type":44},"2024-08-26","ACTUAL",{"date":46,"type":20},"2024-08",{"date":48,"type":20},"2026-12",{"name":50,"class":51},"Spanish Society of Cardiology","OTHER",""]